-
Electronic (PDF)
-
Site License
-
Enterprisewide
Partial Seizure - Pipeline Review, Q4 2010
Global Markets Direct, December 2010, Pages: 44
Partial Seizure - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Partial Seizure Pipeline Review, Q4 2010”, provides an overview of the Partial Seizure therapeutic pipeline. This report provides information on the therapeutic development for Partial Seizure , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Partial Seizure . “Partial Seizure -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Partial Seizure .
- A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Partial Seizure pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- A snapshot of the global therapeutic scenario for Partial Seizure .
- A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Partial Seizure pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Partial Seizure Overview
Therapeutics Development
An Overview of Pipeline Products for Partial Seizure
Partial Seizure Therapeutics under Development by Companies
Partial Seizure Therapeutics under Investigation by Universities/Institutes
Companies Involved in Partial Seizure Therapeutics Development
Valeant Pharmaceuticals International
Teva Pharmaceutical Industries Limited
UCB Group
Eisai Inc.
Upsher-Smith Laboratories, Inc.
Universities/Institutes Involved in Partial Seizure Therapeutics Development
Partial Seizure Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Brivaracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E2007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retigabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
USL255 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vimpat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Partial Seizure - Featured News
Dec 07, 2010: UCB Reports Long-term Use Of Vimpat C-V Effectively Reduces Partial-Onset Seizure Frequency
Dec 06, 2010: Upsher-Smith Reports Positive Pharmacokinetic Results From Phase I Study Of Extended-Release Topiramate
Dec 01, 2010: GSK And Valeant Receive FDA Complete Response Letter For Ezogabine
Nov 09, 2010: Upsher-Smith Initiates Open-Label Extension Study Of USL255 For Adjunctive Treatment Of Partial-Onset Epilepsy
Oct 14, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy For GABITRIL
Apr 15, 2010: Data presented at the American Academy of Neurology Meeting demonstrated long-term efficacy and tolerability of Vimpat (lacosamide)
Dec 07, 2009: UCB Announces the New Findings on Vimpat, Supports Long-term usage of Vimpat
Dec 02, 2009: Upsher-Smith Announces Milestone In Development Of CNS Strategy
Oct 23, 2009: Valeant Provides Update On Retigabine
Jun 29, 2009: New analysis of pooled clinical data showed Vimpat (lacosamide) significantly improved partial-onset seizure control, increased seizure freedom rates and enhanced patient function
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
